Nanotech Is “More Than Just Tiny,” Requires FDA Regulation – Lawsuit
This article was originally published in The Rose Sheet
Executive Summary
A suit filed in U.S. District Court Dec. 21 by coalition of advocacy groups says FDA's failure to respond "meaningfully" to 2006 citizen petition on nanotechnology violates federal law. Lawsuit asks court to order FDA to respond to their peititon without further delay.
You may also be interested in...
FDA Questions Spray Sunscreen Safety, Efficacy & Monograph Status
FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.
FDA Takes “Property”-Based Approach To Nanotech, Raises Roof To 1 Micron
In its newly released guidance to industry, FDA indicates that “agglomerates and aggregates” of materials that exceed the oft-cited ceiling of 100 nanometers may still warrant consideration as nanotechnology based on their “properties,” a position that could impact the cosmetics sector.
Nanomaterial Sunscreens Should Be Designated “New Drugs” – Petition
FDA should amend the OTC final sunscreen monograph to specify that products containing engineered nanoparticles are excluded and designate the formulas "new drugs," a coalition of public interest groups states in a citizen petition